Article
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Journal of gastroenterology - 1 Jul 2017
Mawatari Seiichi, Oda Kohei, Tabu Kazuaki, Ijuin Sho, Kumagai Kotaro, Inada Yukiko, Uto Hirofumi, Hiramine Yasunari, Kure Takeshi, Fujisaki Kunio, Hashiguchi Masafumi, Hori Takeshi, Oshige Akihiko, Imanaka Dai, Saishoji Akiko, Taniyama Oki, Sakae Haruka, Tamai Tsutomu, Moriuchi Akihiro, Ido Akio
Abstract excerpt
BACKGROUND: Daclatasvir (DCV) and asunaprevir (ASV) combination therapy has been primarily used in patients without NS5A L31 or Y93 resistance-associated substitutions (RASs) before treatment. We examined the characteristics of patients without these baseline RASs who did not achieve hepatitis C virus eradication with DCV and ASV combination therapy and identified new baseline NS5A RASs that are closely...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.